

Volume 7, No. 4, July 2017 \* Bimonthly

ISSN: 2251-9939

# Journal of Life Science and Biomedicine



Available online at [www.jlsb.science-line.com](http://www.jlsb.science-line.com)

*Published by  
Scienceline Publications*



## Editorial Team

### **Editor-in-Chief: Parham Jabbarzadeh Kaboli**

PhD of Molecular Biology and Cancer researcher; Faculty of Medicine and Health Sciences, University Putra, Malaysia ([Website](#); [Emails: researchgroups@drugdiscovery.ir](#))

### **Managing Editor: Yusuf Kaya**

PhD, Professor of Biology, Atatürk University, Erzurum, ([Website](#), [Email: ykaya@atauni.edu.tr](#))

### **Executive Editor: Zohreh Yousefi**

PhD candidate, Biosystematics, Atatürk University, Erzurum, Turkey ([Emails: zohreh.yousefi12@ogr.atauni.edu.tr](#))

### **Language Editor: Samuel Stephen Oldershaw**

Master of TESOL, The Humberston School & The Grimsby Institute, Nuns Corner, Grimsby, North East Lincolnshire, United Kingdom ([Email: s.s.oldershaw@hotmail.com](#))

## Associate Editors

### **Aleksandra K. Nowicka**

PhD, Pediatrics and Cancer researcher; MD Anderson Cancer Center, Houston, Texas, USA ([Email: aknowicka@mdanderson.org](#))

### **Paola Roncada**

PhD, Pharmacokinetics, Residues of mycotoxins in food and in foodproducing species, University of Bologna, Italy ([Email: paola.roncada@unibo.it](#))

### **Tohid Vahdatpour**

PhD, Assistant Prof., Physiology, Islamic Azad University, Iran ([Website](#); [Scopus](#); [Emails: vahdatpour@iaushab.ac.ir](#))

### **Veghar Hejazi**

MD, Tabriz University of Medical Sciences, Tabriz, Iran ([Email: vegharhejazi@gmail.com](#))

### **Nefise Kandemir**

MD, PhD, Department of Medical Genetics, Erciyes University, Kayseri, Turkey

## Reviewers

### **Abolghasem Yousefi**

PhD, Assistant Professor of Anesthesiology, Tehran University of Medical Sciences, Tehran, Iran ([Website](#); [Email: ayousefi@gmail.com](#))

### **Aleksandra K. Nowicka**

PhD, Pediatrics and Cancer researcher; MD Anderson Cancer Center, Houston, Texas, USA ([Email: aknowicka@mdanderson.org](#))

### **Amany Abdin**

PhD, Pharmacology; MSc, Medical Biochemistry; Tanta University, Egypt ([Emails: amanyabdin@med.tanta.edu.eg, amanynhr@hotmail.com](#))

### **Babak Yousefi**

Physician, General Surgery Resident at Hamedan University of Medical Science, Hamedan, Iran

### **Fazal Shirazi**

PhD, Infectious Disease researcher at MD Anderson Cancer Center, Houston, Texas, USA

### **Fikret Çelebi**

Professor of Veterinary Physiology; Atatürk University, Turkey ([Website](#); [Email: fncelebi@atauni.edu.tr](#))

**Ghada Khalil Al Tajir**

PhD, Pharmacology, Faculty of Medicine, UAE University, Al Ain, UAE

**M.R. Ghavamnasiri**

PhD, Professor of Oncology at Omid Cancer Hospital, MUMS; Cancer Research Center, Mashhad University of Medical Sciences, Iran

**Kaviarasan Thanamegm**

PhD of Marine Bioactive compounds, Department of Ecology and Environmental Sciences, Pondicherry University, India ([Email: marinekavi@gmail.com](mailto:marinekavi@gmail.com))

**Jahan Ara Khanam**

PhD, Anti-cancer Drug Designer and Professor of UR; Department of Biochemistry and Molecular Biology, University of Rajshahi, Bangladesh

**Mozafar Bagherzadeh Homaei**

PhD, Plant Physiology, University of Isfahan, Isfahan, Iran

**Osman Erganiş**

Professor, PhD, Veterinary Microbiology, Selcuk University, Konya, Turkey

**Paola Roncada**

PhD, Pharmacokinetics, Residues of mycotoxins in food and in foodproducing species, University of Bologna, Italy ([Email: paola.roncada@unibo.it](mailto:paola.roncada@unibo.it))

**Perumal Karthick**

Professor, PhD, Marine Biology, Pondicherry University, Brookshabad Campus, Port Blair, Andamans. 744112, India ([Email: karthickmicrobes@gmail.com](mailto:karthickmicrobes@gmail.com))

**Reza Khodarahmi**

PhD, Biochemistry at KU; Pharmacy School, Kermanshah University, Kermanshah, Iran

**Saeid Chekani Azar**

PhD, Veterinary Physiology, Atatürk University, Erzurum, Turkey ([Google Scholar](https://scholar.google.com/citations?user=saeid.azar); [Emails: saeid.azar@atauni.edu.tr](mailto:saeid.azar@atauni.edu.tr); [schekani@gmail.com](mailto:schekani@gmail.com))

**Siamk Sandoughchian**

PhD Student, Immunology, Juntendo University, Japan

**Siva Sankar. R.**

PhD, Marine Biology, Dept. of Ecology & Environmental Sciences, Pondicherry University, Puducherry - 605014, India ([Email: sivauniverse@gmail.com](mailto:sivauniverse@gmail.com))

**Tohid Vahdatpour**

PhD, Assistant Prof., Physiology, Islamic Azad University, Iran ([Website](#); [Scopus](#); [Google Scholar](#); [Emails: vahdatpour@iaushab.ac.ir](mailto:vahdatpour@iaushab.ac.ir))

**Veghar Hejazi**

MD, Tabriz University of Medical Sciences, Tabriz, Iran ([Email: vegharhejazi@gmail.com](mailto:vegharhejazi@gmail.com))

**Yusuf Kaya**

PhD, Professor of Plant Biology, Atatürk University, Erzurum, Turkey ([Email: ykaya@atauni.edu.tr](mailto:ykaya@atauni.edu.tr))

**Join JLSB Team**

*Journal of Life Sciences and Biomedicine* (JLSB) as international journal is always striving to add diversity to our editorial board and operations staff. Applicants who have previous experience relevant to the position they are applying for may be considered for more senior positions (Section Editor) within JLSB. All other members must begin as Deputy Section Editors before progressing on to more senior roles. Editor and editorial board members do not receive any remuneration. These positions are voluntary.

If you are currently an undergraduate, M.Sc. or Ph.D. student at university and interested in working for JLSB, please fill out the application form below. Once your filled application form is submitted, the board will review your credentials and notify you within a week of an opportunity to membership in editorial board.

If you are PhD, assistant, associate editors, distinguished professor, scholars or publisher of a reputed university, please rank the mentioned positions in order of your preference. Please send us a copy of your resume (CV) or your [ORCID ID](#) or briefly discuss any leadership positions and other experiences you have had that are relevant to applied Medical and Pharmaceutical Researches or publications. This includes courses you have taken, editing, publishing, web design, layout design, and event planning. If you would like to represent the JLSB at your university, join our volunteer staff today! JLSB representatives assist students at their university to submit their work to the JLSB. You can also, registered as a member of JLSB for subsequent contacts by email and or invitation for a honorary reviewing articles.

Contact us at: [editors@jlsb.science-line.com](mailto:editors@jlsb.science-line.com)

Download [Application Form \(.doc\)](#)

## Volume 7 (4); July 25, 2017

## Research Paper

**Clinical and Immunological Evaluation of FarGALS Efficacy during the Process of Adaptation in Patients with Removable Plate Prosthesis Depending on Age.**

Nigmatullaevich AA.

*J. Life Sci. Biomed.*, 7(4): 37-41, 2017;

pii:S225199391700007-7

**Abstract**

Patient adaptation to complete removable plate prosthetics (different types) is one of the acute problems for dental specialists. In addition, some factors including the negative impact of prosthetics on the condition of prosthetic bed, the function of the salivary glands, immunological reactivity, microbiological diversity of oral cavity and insufficient quality of prosthetics manufacture and design features, contribute to the problem. This study aimed to evaluate FarGALS efficacy during the process of adaptation in patients with removable plate prosthesis depending on age. Patients were divided into two control and treatment groups consisted of 3 internal patient groups. Control group included 19, 43 and 37 patients (1<sup>st</sup>-3<sup>rd</sup>, respectively) was treated with the traditional method. Treatment group included 23, 52 and 45 patients (1<sup>st</sup>-3<sup>rd</sup>, respectively) was treated with FarGALS. Patients of this group after meal at bedtime performed the processing of removable plate prostheses and rinsing them 3-4 times during the day by diluting FarGALS with distilled water (1: 4). Antibacterial and anti-inflammatory properties of the drug FarGALS directed against the risk of pathogen attachment and appearance of inflammation in the oral cavity. Therefore, optimal conditions are created to stimulate the activity of neutrophilic leukocytes and macrophages, which leads to the destruction of pathogens of inflammatory surfaces, and intensive filling of the mucosal defects. In conclusion, FarGALS is safe and effective drug which can be used in patients with removable plate prosthesis.

**Keywords:** Plate Prosthetics, Inflammation, FarGALS[Full text-[PDF](#)] [XML]

## Review

**A Review of the Effects of Electromagnetic Fields on Telomere-Dependent Life Span in Human and Experimental Animal Models.**


Chekani Azar S.

*J. Life Sci. Biomed.*, 7(4): 42-50, 2017;

pii:S225199391700008-7

**Abstract**

At current decade, electromagnetic fields (EMFs) and its beneficial or hazardous biological effects is subject of so many studies on human and animals. This paper reviews the effects of EMFs on telomere shortening throughout the life span of human and some animal models and also the importance of major antioxidants in reducing the damage caused by free radicals in the body under exposures. Some studies tried to show the role of oxidative stress in telomere shortening that inevitably directed biological experiments to the use of antioxidant vitamins for telomere stability. Based mainly on biological and epidemiological studies, *in vitro* experiments not only showed positive results with antioxidants, but *in vivo* studies are always getting attention, due to other biological factors that might influence the telomere shortening. Telomere length and telomerase activity assessed in animal cells, tissues and organs may determine telomere stability (off-again) and carcinogenesis (on-again) relationship and life span. In contrast to human, rodent telomeres are generally much longer and express telomerase in many tissues. The rapid death following reproduction observed in rodent especially mouse species is much different and so these model organisms are not a good representative of human aging mechanisms. However, the rat model might be more feasible than mice in studying the effect of oxidative stress and ageing. Animal models such as dogs, bird species, and cattle have been observed that does share more similarities in telomere and telomerase biology with humans, respectively. Although, investigations indicate that telomere length and telomerase activity can be a promising genetic biomarker for chronic oxidative stress caused by free radicals due to long-term exposure to environmental factors like EMFs as part of human daily lives, but there is a need for more research on the role of telomere shortening on inflammatory diseases progression, cancer and the various factors leading to cell senescence, such as heredity and other ageing.

**Keywords:** Human and Animal studies, Electromagnetic fields (EMFs), Mobile phone, Radiation, Health risk, Oxidative stress, Telomerase, Telomere shortening, Cancer, Ageing, Antioxidants[Full text-[PDF](#)] [XML]

# Journal of Life Science and Biomedicine



**ISSN:** 2251-9939

**Frequency:** Bimonthly

**Current Issue:** 2017, Vol: 7, Issue 4 (July)

**Publisher:** [SCIENCELINE](#)

The Journal of Life Science and Biomedicine is aimed to improve the quality and standard of life with emphasis on the related branches of science such as biology, physiology, biochemistry, zoology, anatomy, pathology and their applications and innovations in medicine and healthcare... [view full aims and scope](#)

<http://jlsb.science-line.com>

» JLSB indexed/covered by [NLM Catalog](#), [RiCest \(ISC\)](#), [Ulrich's™](#), [SHERPA/RoMEO](#), [Genamics](#), [Google Scholar \(h-index= 10\)](#), [Index Copernicus](#), [ICV2015: 66.26...](#) [details](#)

» Open access full-text articles is available beginning with Volume 1, Issue 1.

» Full texts and XML articles are available in ISC-RiCest.

» This journal is in compliance with [Budapest Open Access Initiative](#) and [International Committee of Medical Journal Editors' Recommendations](#).

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

» High visibility of articles over the internet.

» Publisher Item Identifier [...details](#)

» This journal encourage the academic institutions in low-income countries to publish high quality scientific results, free of charges... [view Review/Decisions/Processing/Policy](#)



[ABOUT US](#)

| [CONTACT US](#)

| [PRIVACY POLICY](#)

## Editorial Offices:

Atatürk University, Erzurum 25100, Turkey

University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada

University of Maragheh, East Azerbaijan, Maragheh 55136, Iran

Homepage: [www.science-line.com](http://www.science-line.com)

Phone: +98 914 420 7713 (Iran); +90 538 770 8824 (Turkey); +1 204 8982464 (Canada)

Emails:

[administrator@science-line.com](mailto:administrator@science-line.com)

[saeid.azar@atauni.edu.tr](mailto:saeid.azar@atauni.edu.tr)

# Clinical and Immunological Evaluation of FarGALS Efficacy During the Process of Adaptation in Patients with Removable Plate Prosthesis Depending on Age

Avzal Nigmatullaevich Akbarov ✉

Tashkent State Dental Institute, Tashkent, Uzbekistan

✉Corresponding author's Email: azam746@mail.ru

## ABSTRACT

Patient adaptation to complete removable plate prosthetics (different types) is one of the acute problems for dental specialists. In addition, some factors including the negative impact of prosthetics on the condition of prosthetic bed, the function of the salivary glands, immunological reactivity, microbiological diversity of oral cavity and insufficient quality of prosthetics manufacture and design features, contribute to the problem. This study aimed to evaluate FarGALS efficacy during the process of adaptation in patients with removable plate prosthesis depending on age. Patients were divided into two control and treatment groups consisted of 3 internal groups. Control group included 19, 43, and 37 (1<sup>st</sup>-3<sup>rd</sup>, respectively) was treated with the traditional method. Treatment group included 23, 52, and 45 (1<sup>st</sup>-3<sup>rd</sup>, respectively) was treated with FarGALS. Patients of this group after meal at bedtime performed the processing of removable plate prostheses and rinsing them 3-4 times during the day by diluting FarGALS with distilled water (1:4). Antibacterial and anti-inflammatory properties of the drug FarGALS directed against the risk of pathogen attachment and appearance of inflammation in the oral cavity. Therefore, optimal conditions are created to stimulate the activity of neutrophilic leukocytes and macrophages, which leads to the destruction of pathogens of inflammatory surfaces, and intensive filling of the mucosal defects. In conclusion, FarGALS is safe and effective drug which can be used in patients with removable plate prosthesis.

## Original Article

PII: S225199391700007-7

Rec. 05 Jun. 2017  
Acc. 13 Jul. 2017  
Pub. 25 Jul. 2017

## Keywords

Plate Prosthetics,  
Inflammation,  
FarGALS

## INTRODUCTION

In the current era, there is an urgent need for production of new effective drugs against pathogenic microorganisms resistant to current antibiotics and chemotherapeutic treatment [1]. In this regard, the high antimicrobial activity of a new biotechnological drug (FarGALS) against a wide spectrum of pathogenic microorganisms, suggests that it can be effective against the risk of pathogen attachment and appearance of inflammation in the oral cavity or in treatment of different diseases associated with this pathogen [1-3].

Adaptation to complete removable plate prosthetics is acute problem for dental specialists. The negative influence of prosthetics on the prosthetic bed of the oral cavity, the function of the salivary glands, immunological reactivity, microbiological diversity and insufficient quality of prosthetics contribute to the actuality of the problem. It is especially relevant to the elderly patients; at who, along with the complete loss of dental rows, the adaptive capabilities of the body, including the oral cavity, are sharply reduced and do not positively resist the negative effects associated with removable prosthesis [4-6].

Unreasonable and uncontrolled use of chemotherapy leads to the formation of strains with resistance to drugs. This can be avoided by using antiseptic drugs that have a broad antibacterial spectrum and do not induce microbial resistance [6-9]. Further application of the medicinal forms of antiseptics for topical application is undoubtedly a very promising direction, as it allows changing the nature of the effect on the humoral and cellular inflammation factors in the adaptation period while using complete removable plate prostheses [6, 7, 10].

The particular interest from the point of view of the use of new medicines forms for the use of complete removable plate prostheses lays in the influence of FarGALS on local immunity and bacteriological parameters of the oral cavity of elderly patients using complete removable plate prostheses and on the process of adaptation to them. The drug FarGALS is included in the pharmacotherapeutic group: antiseptic wound-healing agents.

## MATERIAL AND METHODS

Patients were divided into two control and treatment groups. Control group consisted of 3 internal groups included 19 patients as 1<sup>st</sup> group, 43 as 2<sup>nd</sup> group, 37 as 3<sup>rd</sup> group, was treated with the traditional method. Treatment group consisted of 3 internal groups included 23 patients as 1<sup>st</sup> group, 52 as 2<sup>nd</sup> group, 45 as 3<sup>rd</sup> group, was treated with FarGALS. Patients of treatment group after meal at bedtime performed the processing of removable plate prostheses and rinsing them 3-4 times during the day by diluting FarGALS with distilled water (1: 4).

Patients of group 1 were from 40 to 59 year-old after the start of traditional therapy. Patients of 2<sup>nd</sup> group were from 60 to 74 year-old and patients of 3<sup>rd</sup> group were from 75 to 90 year-old. At the background of the treatment, immunological and microbiological studies were conducted in dynamics with admission, and data were collected on day 15, and day 30 of treatment.

### Ethical approval

The review board and ethics committee approved the study protocol and informed consents were taken from all the participants.

## RESULTS AND DISCUSSION

As has been shown in elderly patients with complete absence of teeth, at the seeking orthopedic care, there is a violation of local immunity in the form of deficiency of PhAN (Phagocyte Activity of Neutrophils), PhI (Phagocytose Index), lysozyme, secretory sIgA in the oral cavity, depending on the age aspect. In this connection, it is of interest to study the effectiveness of the current therapy of impaired local immunity in the process of adaptation to removable prostheses, depending on the method of treatment for these body indices. The results of the study are presented in Table 1.

**Table 1.** Level of content of local immunity parameters in mixed saliva in patients of the 1<sup>st</sup> group (from 40 to 59 years) with orthopedic treatment in dynamics.

Items	Indicators	Baselines	15 days after treatment	30 days after treatment
Control group	PhAN in %	52.8 ± 0.82	54.4 ± 2.8	46.6 ± 2.26 <sup>* #</sup>
	PhI	4.06 ± 0.82	4.12 ± 0.21	3.95 ± 0.17
	Lysozyme (mg/ml)	19.3 ± 0.46	28.8 ± 0.86 <sup>**</sup>	19.5 ± 0.62 <sup>##</sup>
	SlgA (µg/l)	199 ± 6.0	226 ± 8.3 <sup>*</sup>	188 ± 9.2 <sup>#</sup>
Treatment Group	PhAN in %	52.8 ± 0.82	60.4 ± 1.9 <sup>** °</sup>	52.0 ± 1.24 <sup>## °</sup>
	PhI	4.06 ± 0.82	4.83 ± 0.19 <sup>** °</sup>	4.28 ± 0.17 <sup>##</sup>
	Lysozyme (mg/ml)	19.3 ± 0.46	32.2 ± 0.90 <sup>** °</sup>	20.4 ± 0.58 <sup>##</sup>
	SlgA (µg/l)	199 ± 6.0	302 ± 7.8 <sup>** ° °</sup>	205 ± 7.9 <sup>##</sup>

The reliability of differences from baseline (\*\*: P<0.001 and \*: P<0.05); Data from 15 days (##: P<0.001 and #: P<0.05); and control data (°: P<0.001 and °: P<0.05). PhAN = Phagocyte Activity of Neutrophils; PhI = Phagocytose Index.

As can be seen from the data of Table 1, in patients of group 1 (from 40 to 59 years after the start of traditional therapy), in patients receiving treatment with removable prostheses and oral rinsing, there were insignificant positive shifts in PhAN, lysozyme and sIgA values in local immunity on the 15th day of the study and were respectively 54.9±1.1%; 22.7±0.83 mg/ml and 226 ± 8.3 µg/l. It can be seen that only the lysozyme and sIgA

values are significantly higher in comparison with the initial indices ( $P<0.001$  and  $P<0.05$ ), respectively. However, on day 30 of the study, the local immunity indices of the 1<sup>st</sup> group of patients examined were below the normative value.

A very different picture was observed in group 1 patients (from 40 to 59 years after initiation of therapy (local treatment by FarGALS) on the day 15. a significant increase was observed on the part of the phagocytic index of neutrophils: if in the given group, on admission, the PhAN was averaged  $52.8 \pm 0.82\%$ , in the process of treatment with FarGALS, this index averaged  $60.4 \pm 1.9\%$  and the number of positive samples normalized, these values were significantly higher in relation to the parameters before treatment ( $P<0.001$ ) and the control group ( $P<0.05$ ). However, at the FN of neutrophils derived indicators have not changed significantly in the first group of patients throughout the study and the number of positive samples in 30 days was equal to 26.1%.

Application of FarGALS drug in the patients of the treatment group led to the activation performance of lysozyme and slgA content in the saliva of patients. At the patients aged 40 to 59 years, baseline activity of lysozyme and slgA were  $19.0 \pm 0.46$  mg/ml and  $199 \pm 6.0$  g/l, whereas after use of FarGALS preparation for rinsing the mouth lysozyme activity and slgA increased sharply and correspondingly was  $32.2 \pm 0.9$  mg/ml and  $302 \pm 7.5$  µg/l, the differences were statistically significant compared to the initial values of the control groups ( $P<0.001$ ), respectively. The normalized water permeability (NWP) indicators also normalized. After adaptation to removable dentures by 30<sup>th</sup> day, these indicators came close to the initial indicators.

At the patients from 60 years to 74, PhAN content and lysozyme before and after using traditional mouthwash increased after 15 days, respectively, was  $48.5 \pm 0.78\%$  and  $51.9 \pm 1.1\%$ ;  $17.3 \pm 0.53$  and  $22.7 \pm 0.83$  mg/ml ( $P<0.05$  and  $P<0.001$ ), the differences are statistically significant (Table 2). NWP was 20.9% and 13.9% in the group. It revealed significant shifts reliable indicators from the FF and slgA oral cavity after 15 days ( $P>0.05$ ), respectively, and found significantly higher NWP (27.9% and 30.2%). in other words, after 15 days at 43/13 patients local immunity of the oral cavity In the 2nd group after using the traditional mouth rinse is weakened.

**Table 2.** The level of local immunity in the mixed saliva of the patients of 2<sup>nd</sup> group (60 to 74 years) in orthopedic treatment in the dynamics

Items	Indicators	Baselines	15 days after treatment	30 days after treatment
Control group	PhAN in %	$48.5 \pm 0.78$	$51.9 \pm 1.1^*$	$45.2 \pm 1.31^{* \# \#}$
	PhI	$3.68 \pm 0.07$	$3.92 \pm 0.12^*$	$2.81 \pm 0.17^{* \# \#}$
	Lysozyme (mg/ml)	$17.3 \pm 0.53$	$22.7 \pm 0.83^{**}$	$15.6 \pm 0.75^{* \# \#}$
	SlgA (µg/l)	$180 \pm 8.9$	$200 \pm 5.8$	$167 \pm 4.56^{* \# \#}$
Treatment Group	PhAN in %	$48.5 \pm 0.78$	$55.1 \pm 1.2^{* \# \# \circ}$	$49.7 \pm 1.9^{\#}$
	PhI	$3.68 \pm 0.07$	$4.12 \pm 0.13^{* \# \#}$	$3.76 \pm 0.09^{\# \circ \circ}$
	Lysozyme (mg/ml)	$17.3 \pm 0.53$	$25.7 \pm 0.88^{* \# \# \circ}$	$19.6 \pm 0.57^{* \# \# \circ \circ}$
	SlgA (µg/l)	$180 \pm 8.9$	$238 \pm 4.5^{* \# \# \circ \circ}$	$192 \pm 5.6^{* \# \# \circ \circ}$

The reliability of differences from baseline (\*\*:  $P<0.001$  and \*:  $P<0.05$ ); Data from 15 days (##:  $P<0.001$  and #:  $P<0.05$ ); and control data (°:  $P<0.001$  and °:  $P<0.05$ ). PhAN = Phagocyte Activity of Neutrophils; PhI = Phagocytose Index.

As shown by the results of studies in table 2, after 30 days of continuous use of complete removable dentures, despite the fact that patients regularly rinsed the mouth and dentures with conventional rinse oral fluid, a significant decrease in the level slgA- 12.1%, reduced lysozyme activity - 11.7%, PhAN - 15.8%, and the FF of 21.7% in saliva are reported compared with the control data.

At patients of the treatment groups by rinsing oral cavity and processing complete dentures with "FarGALS" positive local immunity changes are marked. After 15 days after the professional oral hygiene and the processing of dentures with "FarGALS" the level of local immunity (PhAN, the FF, lysozyme and slgA) in all patients was increased. And correspondingly, the average indices for the group was  $55.1 \pm 1.1\%$ ;  $4.12 \pm 0.13$ ;  $25.7 \pm 0.88$  mg/ml and  $238 \pm 4.5$  mkg/l, the differences are statistically significant ( $P<0.001$ ), respectively, with the baseline level. And the number of positive probes was only for the PhAN and PhI indicators 11.6%. With other words 88.4% of the surveyed subjects normalized. We also note that on the 15th day of the study, the local immunity indices (PhAN, PhI, lysozyme and slgA) in patients within the 2-group (from 60 to 74 years) were significantly higher in comparison with the indices of patients in group 1 ( $P<0.05$ ,  $P<0.05$ ,  $P<0.001$  and  $P<0.001$ ), respectively. On the 30th day, these indicators decreased and were within the initial values. Indices of local immunity (PhAN, PhI, lysozyme and slgA) in patients of senile age (from 75 to 90 years) with orthopedic treatment in dynamics are given in Table 3.

**Table 3.** Level of content of local immunity parameters in mixed saliva in patients of 3<sup>rd</sup> group (from 75 to 90 years) with orthopedic treatment in dynamics.

Items	Indicators	Baselines	15 days after treatment	30 days after treatment
Control group	PhAN in %	45.5 ± 0.90	47.1 ± 1.21	41.0 ± 1.85 <sup>*</sup>
	PhI	3.23 ± 0.1	3.61 ± 0.13 <sup>*</sup>	2.75 ± 0.18 <sup>*##</sup>
	Lysozyme (mg/ml)	16.6 ± 0.53	20.3 ± 0.39 <sup>**</sup>	14.5 ± 0.78 <sup>*##</sup>
	SIgA (µg/l)	169 ± 3.2	185 ± 8.3	156 ± 4.2 <sup>#</sup>
Treatment Group	PhAN in %	45.5 ± 0.90	51.9 ± 1.51 <sup>**°</sup>	46.1 ± 1.41 <sup>##°</sup>
	PhI	3.23 ± 0.1	3.94 ± 0.12 <sup>**°</sup>	3.76 ± 0.17 <sup>°</sup>
	Lysozyme (mg/ml)	16.6 ± 0.53	21.7 ± 0.52 <sup>**°</sup>	17.5 ± 0.81 <sup>##°</sup>
	SIgA (µg/l)	169 ± 3.2	196 ± 5.2 <sup>*</sup>	167 ± 4.7 <sup>##</sup>

The reliability of differences from baseline (\*\*: P<0.001 and \*: P<0.05); Data from 15 days (##: P<0.001 and #: P<0.05); and control data (°: P<0.001 and °: P<0.05). PhAN = Phagocyte Activity of Neutrophils; PhI = Phagocytose Index.

As can be seen from the data given in Table 3 in patients of group 3 (from 75 to 90 years), after traditional therapy (with the processing of removable prostheses and rinsing the oral cavity) on the side of local immunity, the heterogeneous responses of PhAN, lysozyme and sIgA were observed on the 15th day of the study. It can be seen from the table that in all patients only the indices of PhI and lysozyme increased insignificantly. And accordingly, the average indices for the group were 3.23±0.1 and 16.6±0.53 mg/ml and above 3.61±0.13 and 20.3±0.39 mg / ml, the differences are statistically significant in comparison with initial indices (P<0.05 and P<0.001). The normalized water permeability (NWP) decreased by 54.8% and 32.9 to 35.4%. From the side indicators PhAN and sIgA on the 15 day study significant positive changes in comparison Baseline not detected (P>0.05), respectively. In the course of traditional treatment on the 30th day of the study, the local immunity indices significantly decreased in comparison with the baseline and control group parameters (P<0.001) and a sharp increase in NWP to (48.8, 57.3 and 46.3%), respectively were observed. Apparently, with the aging of the organism and the insufficiency of individual links of nonspecific immunity and the weakness of the controlling parts of the immune system in patients of senile age, a sharp decrease in the response of local immunity to the inflammatory process of the oral cavity occurred after removal of removable prostheses.

In patients of senile age, the main treatment groups when treating the oral cavity and rinsing complete removable dentures with FarGALS, a positive shift of changes in local immunity is noted 15 days after orthopedic treatment. The level of local immunity (PhAN, PhI, lysozyme and sIgA) in all patients significantly increased (P<0.001), respectively, compared with baseline. Moreover, the number of positive probes also decreased and amounted to an average of the group (26.6, 35.6, 24.4%). In other words, in 2/3 of the patients after the treatment, local immunity parameters were restored. After adaptation to removable dentures by 30<sup>th</sup> day, these indicators approached the initial values.

Thus, when studying the dynamics of the values (PhAN, PhI, lysozyme and sIgA) of these indices, it was shown that in patients in the treatment group, after the use of the FarGALS drug in orthopedic practice, there was a significant increase, in contrast to the comparison group, local immunity in all examined groups, which suggested a positive effect of FarGALS on local immunity. Despite extremely unfavorable conditions for the functioning of the tissues of the prosthetic bed, the use of FarGALS resulted in positive effects, that led to the preservation of the initial level of local immunity and the clinical effect after the application of prostheses. Whereas with traditional orthopedic treatment, this indicator significantly worsened after the application of prostheses, with further aggravation of this negative effect over time. It should be noted that the most pronounced differences between the patients of the observation and comparison groups were noted in the early period, that is, up to 15 days of treatment. An increase in the local immunity index indicates the activation of nonspecific immune defense of the oral cavity in patients of the treatment group. The increase in PhAN and FF indicates a response to pathogenic microorganisms, which are noted in patients with complete absence of teeth. PhAN and FF in the observed patients of the treatment group, were decreased by 30<sup>th</sup> day, which indicates the relief of inflammation.

## CONCLUSION

In our opinion, antibacterial and anti-inflammatory properties of the drug FarGALS directed against the risk of pathogen attachment and appearance of inflammation in the oral cavity. As a result, optimal conditions are created to stimulate the activity of neutrophilic leukocytes and macrophages, which leads to the destruction of pathogens of inflammatory surfaces, intensive filling of the mucosal defect. The absence of an irritant effect on the mucous retains its integrity. The intact mucosa, especially the tissues of the prosthetic bed, is an important source of the epithelial layer covering erosion: the microenvironment activates a sufficient number of viable cells that activate healing, thereby guaranteeing the preservation of the oral microbiocenosis.

### Acknowledgments

This work was supported by Tashkent State Dental Institute, Tashkent, Uzbekistan.

### Competing interests

The author declares that they have no competing interests.

## REFERENCES

1. Bajenov LG, Kasimov SZ, Rizaeva EV, Shanieva ZA. 2011. The New Biotechnological medication "FarGALS" and its antimicrobial properties. In: Mikhalovsky S., Khajibaev A. (eds) *Biodefence. NATO Science for Peace and Security Series A: Chemistry and Biology*. Springer, Dordrecht. DOI: 10.1007/978-94-007-0217-2\_16
2. Bazhenov LG, Mustamov AN, Ekubzhonov FT, Bazhenov SS, Shanieva ZA. 2008. Antimicrobial activity of the new biotechnology drug "FarGALS" and the prospects for its clinical application. *Bulletin of the International Scientific Surgical Association*. 3(1): 23-25.
3. Umarovich NN. 2017. FarGALS efficiency in complex treatment of HIV-infected children with acute purulent sinusitis. *Europ Sci Rev*. pp. 86-88. DOI: <http://dx.doi.org/10.20534/ESR-17-1.2-86-88>
4. Agzamhodjaev SS. 2000. The mechanisms of patient adaptation to dental prosthesis. *Stomatologiya*. 1: 49-54.
5. Alimskiy AV. 2004. To the question of dental prosthetic support in elderly patients living in Moscow and Podmoscowie region. *Stomatology*. 4: 72.
6. Aryutunov SD, Carev VN, Babunashvilli GV et al. 2008. Clinical aspects of microbiology of oral acrylic teeth prosthesis. *Stomatology*. 1: 61-64.
7. Baran I, Nalçacı R. 2008. Self-reported denture hygiene habits and oral tissue conditions of complete denture wearers. *Arch. Gerontol. Geriatr*. Vol. 29.
8. Kimoto S., Kitamura M. 2004. Randomized clinical trial on satisfaction with resilient denture liners among edentulous patients. *Int. J. Prosthodont*. 17: 236-240.
9. Lamfon H, Porter SR, McCullough M, Pratten J. 2003. Formation of *Candida albicans* biofilms on non-shedding oral surfaces. *Eur. J. Oral Sci*. 111(6): 465-471.
10. Okada M, Awane S, Suzuki J. 2002. Microbiological, immunological and genetic factors in family members with periodontitis as a manifestation of systemic disease, associated with hematological disorders. *J. Periodontal Res*. 37(4): 307-315.

# A Review of the Effects of Electromagnetic Fields on Telomere-Dependent Life Span in Human and Experimental Animal Models

Saeid Chekani Azar✉

PhD of Animal Physiology, Faculty of Veterinary Medicine, Atatürk University, Turkey

✉ Corresponding author's Email: saeid.azar@atauni.edu.tr

## ABSTRACT

At current decade, electromagnetic fields (EMFs) and its beneficial or hazardous biological effects is subject of so many studies on human and animals. This paper reviews the effects of EMFs on telomere shortening throughout the life span of human and some animal models and also the importance of major antioxidants in reducing the damage caused by free radicals in the body under exposures. Some studies tried to show the role of oxidative stress in telomere shortening that inevitably directed biological experiments to the use of antioxidant vitamins for telomere stability. Based mainly on biological and epidemiological studies, *in vitro* experiments not only showed positive results with antioxidants, but *in vivo* studies are always getting attention, due to other biological factors that might influence the telomere shortening. Telomere length and telomerase activity assessed in animal cells, tissues and organs may determine telomere stability (off-again) and carcinogenesis (on-again) relationship and life span. In contrast to human, rodent telomeres are generally much longer and express telomerase in many tissues. The rapid death following reproduction observed in rodent especially mouse species is much different and so these model organisms are not a good representative of human aging mechanisms. However, the rat model might be more feasible than mice in studying the effect of oxidative stress and ageing. Animal models such as dogs, bird species, and cattle have been observed that does share more similarities in telomere and telomerase biology with humans, respectively. Although, investigations indicate that telomere length and telomerase activity can be a promising genetic biomarker for chronic oxidative stress caused by free radicals due to long-term exposure to environmental factors like EMFs as part of human daily lives, but there is a need for more research on the role of telomere shortening on inflammatory diseases progression, cancer and the various factors leading to cell senescence, such as heredity and other ageing.

## Review

PII: S225199391700008-7

Rec.	22 Mar.	2017
Acc.	12 Jul.	2017
Pub.	25 Jul.	2017

## Keywords

Human & Animal studies,  
Cellular studies,  
Electromagnetic fields (EMFs),  
Mobile phone,  
Radiation,  
Health risk,  
Oxidative stress,  
Telomerase,  
Telomere shortening,  
Ageing,  
Antioxidants

## INTRODUCTION

Currently people live in an invisible but dangerous ocean of electromagnetic radiation. We believe that cellphones are unhealthy at any speed or we need to be aware of the adverse health effects of environmental factors so that we can have the choice of taking precautions against the exposures. There are critical following questions: What is the evidence that wireless and EMF radiations is dangerous and is disturbing biology and impacting our genetic material and DNA, our present functioning as well as potentially jeopardizing the health of future

generations? What mechanisms can explain the beneficial or hazardous biological effects and links to various conditions? How are the effects of EMFs on telomere shortening, telomerase activity and aging or life span? What is the importance of natural antioxidants, i.e., vitamins A, E and C in reducing the damage caused by free radicals in the body under exposures? Learn why use of time, distance and shielding in radiation protection is important and essential to preserve optimal functioning and fertility, while legal technological efforts are currently pursued to assure safer communications technologies. Hence, to response the questions, findings in this review can provide a better understanding of the subject matter and issues involved.

In this review, special attention is paid to the effects of environmental factors like EMFs on telomere attrition of human and some animal models and also the importance of natural antioxidants in reducing the damage caused by free radicals in the body under exposures.

### **Detrimental effects of EMF on human and experimental animals**

Nowadays, people are under exposure of various types of non-ionizing electromagnetic fields (EMF) that has increased due to wireless or the mobile handset and base station antennas. This new invisible environmental factor can affect gender, tissue density of the body, life span. The exposure levels to electromagnetic fields can penetrate the body and act on all the organs and tissues, altering the cell membrane potential and the distribution of ions and dipoles and therefore influencing the biochemical processes in the cell [1]. It has been reported that waves from the electromagnetic fields of cellular phones, can produce energy distribution and temperature in living tissues [2, 3]. In the long-term, these extremely low frequencies (ELFs) that are the International Telecommunication Union (ITU) designation for electromagnetic radiation (radio waves) with 3 to 30 Hz frequencies, and 100,000 to 10,000 kilometers wavelengths, respectively, cause some variations in the structure and biochemical properties of tissues [4, 5].

At current decade, EMFs and its hazardous or beneficial biological effects is subject of so many researches on human and animal models. In 2004-2005 some significant experiments has been conducted on the effects of EMFs on the nervous and endocrine systems [3, 5-7]. The results suggested that temperature is an important factor in the regulation of the release of endocrine hormones. For example, the activity of thyroid hormones increased under cold temperature and thyroid-stimulating hormone (TSH) secretion from the pituitary, and the release of T3 and T4 from the thyroid increased by acute psychological stress [8]. On the one hand, heat temperature is one of the wide varieties of factors which cause oxidative stress *in-vivo*.

It has been reported that EMFs and MFs cause an increase in lipolysis and glycogenolysis in adipose tissue of rodent model and also an increase in hormones such as thyroxine, glucagon and cortisol of particular interest as a stress indicator secreted by the adrenal glands [7, 10, 11]. Based on human studies of Radon et al. [12] it has been reported that exposure to EMF increased serum cortisol [12]. Vangelova et al. [13] reported significant high levels of stress hormones such as cortisol levels of physiotherapists and nurses due to long-term EMF exposure. The elevated levels of cortisol as a number one of public health enemy, have been known for years that interfere with lower immune function, bone density and learning and memory, increase weight gain, cholesterol, blood pressure, heart disease etc. However, the number of investigations on the negative long/short-term effects of EMFs on endocrine glands are still limited [9].

According to the studies about of biological effects of EMF emitted from cellular phones (GSM: 900MHz) on laboratory animals, it is reported that 900 MHz EMF make to change the rate of some endocrine hormones in the rats [9] and hamsters [14], also, It makes oxidative stress in the rats and rabbits [14, 15]. Lotfi and Shahryar [13] had showed that EMFs emitted by cellular phone can change serum testosterone and lipid concentrations in exposed male hamsters. Some of the related studies with different frequencies of EMF and magnetic fields (MF) showed that Magnetic fields (MFs) and EMFs may cause decrease in total cholesterol and triglyceride of plasma in human and laboratory animals [16-20]. Also, these effects were more significant in longer time period in exposure to MF and EMF [17, 19]. Although there have been many studies in the case of biological effects of EMF with different frequency and time periods, unfortunately it hasn't been studied any possible direct effects of cellular phone EMF (GSM: 900 MHz) on plasma lipids rate such as cholesterol and triglyceride.

Evidences of the hazardous effect of cellular phones on male fertility are still equivocal as studies have revealed a wide spectrum of possible of testicular damage [21]. Shahryar et al. [14] had reported exposure to cellular phones EMF can elevate sex hormone (testosterone) in male hamsters and also can changes secondary sex ratio [22]. It seems that the effects of mobile phones and EMF on progesterone and stress hormone such as cortisol and especially on telomere shortening and life span were not clearly studied in rodent, while more studies were performed on birds or other animal models. Exposure to EMF was studied in poultry at pre-incubation [23], during-


incubation [24, 25] or post-incubation [26]. It has been well documented that when conditions were optimal, chick embryos developed normally and hatched in approximately 21 d [17], but hatchery factors includes turning, vital gas exchange, temperature, humidity and other environmental factors [28] have been shown to affect embryo growth.

The environmental factors that are critical to the development of the embryo occur during the incubation and hatching processes and any alterations in these processes influences the metabolism and growth of embryos with possible consequent at post-hatch life and affect finishing outcome via changes in the efficiency of nutrient metabolism and utilization [29-30]. At current decade, researchers have done focused on other environmental factors in hatching process such as light color [29], electric fields [30] and electromagnetic fields (EMF) [24, 25].

During rearing period, regardless to hazardous effects of fields, EMFs could apply as anti-coccidiosis agent [31]. During incubation, embryonic exposure to EMFs had detrimental effects on embryo development and hatching results [25, 32]. Along with negative effect of EMFs on development, various studies had reported significant [33] or not significant [34] effects of EMFs (50-60 Hz) on organ weight in mammalian models. It seems that late stage exposure to EMF caused slow proliferation and morphogenesis in liver [35]. As regards internal organs, in mammalian model, Erpek et al. [34] had reported that liver weight didn't have significant change in exposure to 50 Hz, 6 mT for two months, 2 h daily. In hatchery experiments, Shafey et al. [30] reported lower proportions of liver plus heart plus gizzard in chicks exposed to electric fields when compared with those of the control birds.

### Telomerase activity, Telomere shortening and aging

Telomerase is a ribonucleoprotein that is an enzyme which adds DNA sequence repeats ("TTAGGG" in all vertebrates) to the 3' end of DNA strands in the telomere regions, which are found at the ends of eukaryotic chromosomes. This region of repeated nucleotide called telomeres contains noncoding DNA and hinders the loss of important DNA from chromosome ends. As a result, every time the chromosome is copied only 100–200 nucleotides are lost, which causes no damage to the organism's DNA. Telomerase is a reverse transcriptase that carries its own RNA molecule, which is used as a template when it elongates telomeres, which are shortened after each replication cycle. Under normal circumstances, telomerase become shorter and shorter with each cycle of cell division. A sufficiently short telomere is believed to signal the cells to stop dividing. In the case of eukaryotic organisms, telomerases are composed of an accumulation of repeated defined nucleotide sequences (repeats), which for example contain the sequence TTAGGG in humans.



**Figure 1.** An illustration of a telomerase molecule. RNA-directed DNA polymerase. A conceptual diagram showing the protein component of telomerase (TERT) in grey and the RNA component (TR) in yellow [Author = Sierra Sciences, LLC (uploaded from intranet, February 19, 2009); Permission = Sierra Sciences has released this diagram under the Creative Commons]

Telomerase activity is expressed in most human tumor tissues but not in normal tissues except those of the germline (testes/ovaries). Stem cells of renewing tissues express very low levels of telomerase. Telomerase activity is occasionally detected in tissues adjacent to tumors possibly reflecting the presence of occult micrometastases.

It has been suggested that telomerase is responsible for the unchecked growth of human cancer cells. Unlike normal cells, in cancer cells telomerase appears to grant the cell immortality by maintaining telomere length so that the cell never receives a signal to stop dividing. The telomerase enzyme is an ideal target for chemotherapy because this enzyme is active in about 90 percent of human tumors, but inactive in most normal cells.

By contrast to stem cells and germ-line cells, telomeres in somatic cells shorten with each cell division leading to cellular senescence (ageing). The enzyme telomerase (cellular reverse transcriptase) is involved in telomere stability by synthesizing a new copy of the repeat by using its RNA template. Bodnar et al. [36] forced expression of telomerase in normal human cells by transfection of retinal pigment epithelial cells and foreskin fibroblasts with a vector encoding the human telomerase enzyme. Remarkably, these cells exhibited elongated telomeres, “divided vigorously”, and proliferated at least 20 doublings beyond their normal life-span; in contrast, the control cells showed shortening of telomeres and senescence [36]. Thus, in typical somatic cells, human telomeres normally undergo shortening at each cell division, and when several kilobases of telomeric DNA is gone, cell division halts and senescence manifests.

Regulation of telomerase activity is an area of intense investigation, but its exact mechanisms are not yet elucidated. The contribution to telomere loss by oxidative DNA damage senescence cells were found to contain 30% more oxidative modified guanine in their DNA. Since oxidative modifications and shortening by reactive oxygen species (ROS) leads to aging of the somatic cells, it is expected that antioxidants and reactive free radical scavengers may play a preventive role and possess anti-ageing properties. Additional evidence for the role of ROS in telomere shortening was associated with chronic oxidative stress and inflammation.

Various models (animal types) have been developed and applied to investigate the relationship between telomere length and oxidative stress. And future studies should investigate the genetic determinants of telomere shortening and stability and to assess the effects of environmental factors that increase oxidative stress and chronic inflammation.

### **Antioxidant: Vitamins E and C**

It has been recognized since the 1940s that vitamin E ( $\alpha$ -tocopherol) is a powerful lipophilic antioxidant that is absolutely vital for the maintenance of mammalian spermatogenesis [37]. It is present in particularly high amounts in Sertoli cells and pachytene spermatocytes and to a lesser extent round spermatids [38].

Vitamin C (ascorbic acid) also contributes to the support of spermatogenesis at least in part through its capacity to reduce  $\alpha$ -tocopherol and maintain this antioxidant in an active state. Vitamin C is itself maintained in a reduced state by a GSH-dependent dehydroascorbate reductase, which is abundant in the testes [39]. Deficiencies of vitamins C or E leads to a state of oxidative stress in the testes that disrupts both spermatogenesis and the production of testosterone [37].

Conversely, ascorbate administration to normal animals stimulates both sperm production and testosterone secretion [40]. This vitamin also counteracts the testicular oxidative stress induced by exposure to pro-oxidants such as arsenic, Bioaccumulation of polychlorinated biphenyl (PCBs) (Arochlor 1254), cadmium, endosulfan and alcohol [41-45]. Furthermore, endogenous ascorbate levels decrease dramatically when oxidative stress is induced in the testes by, for example, chronic exposure to lead, chromium, cadmium or aflatoxin [46-48]. Vitamin E has also been shown to suppress lipid peroxidation in testicular microsomes and mitochondria [49, 50] and to reverse the detrimental effects of oxidative stress on testicular function mediated by exposure to such factors as ozone, iron overload, intensive exercise or exposure to aflatoxin, polychlorinated biphenyls (PCBs), cyclophosphamide and formaldehyde [41, 45, 46, 51-55]. Furthermore testicular vitamin E levels have also been shown to fall significantly when oxidative stress is induced by exposure to pro-oxidant stimuli such as chromium [47]. Therefore, antioxidant nutrient supplementation especially vitamins E, C and A, selenium, zinc and chromium can be used to attenuate the negative effects of environmental factors as stress agents.

## **DISCUSSION**

### **The role of oxidative stress in telomere shortening**

These results and the role of oxidative stress in telomere shortening, inevitably directed biological experiments to the use of antioxidant vitamins in the prevention of telomere shortening [56]. Some studies supported this

suggestion. It was found that age-dependent telomere shortening in human vascular endothelial cells, *in vitro*, could be slowed down by an ascorbic acid derivative (ascorbate-2-O-phosphate). It led to an extension of the cellular life span and prevented cell-size enlargement (cellular indication of senescence) [57]. The same treatment of human embryonic cells with ascorbic acid phosphoric ester magnesium salt decreased the level of oxidative stress, prevented telomere attrition and extended the replicative life span of cells [58]. Another study *in vitro* by Yudoh et al. [59] chondrocyte senescence (risk for cartilage degeneration) has been used. These cells, chondrocytes, cultured in the presence of the oxidant H<sub>2</sub>O<sub>2</sub> showed that oxidative stress induced telomere shortening and replicative senescence, but in the presence of ascorbate-2-O-phosphate the shortening was reduced [59].

Although *in vitro* experiments showed positive results with antioxidants, *in vivo* experiments are considered more important because other biological factor might influence the telomere shortening. Male and female rats were used for these types of experiments. Several oxidative stress markers were studied and the results showed that female rats exhibited longer telomeres than male rats. Expression levels of certain antioxidant enzymes, such as the mitochondrial antioxidant manganese superoxide dismutase (MnSOD), glutathione peroxidase (GPx) and glutathione reductase (GRx), in the renal cortex and medulla were found to be higher in female than in male rats. The explanation is that female rats have higher levels of estrogens, which enhance gene expression of MnSOD. The decreased antioxidant levels may be partially responsible for the age-related kidney telomere shortening [60, 61].

Proliferating fibroblasts exposed to buthionine sulfoximine, which depletes the antioxidant enzyme reduced glutathione (GSH, reduced Glutathione is a linear tripeptide, the molecule has a sulfhydryl (SH) group on the cysteinyl portion, which accounts for its strong electron-donating character), decreased telomerase activity, whereas repletion of cells with glutathione increased telomerase activity in a dose-dependent manner [62].

Italian researcher La Torre et al. in 1997 [63] found that the death of some cell lines was due to the sum of molecular damages caused by free radicals, and the subsequent loss of telomeric DNA. So short of the siRNA inhibition in cancer cells, what interventions can be affected for the health aspects? [64]. We have all heard of free radicals damage and on the contrary, health benefits of antioxidants. Science has progressed to the point that availability of antioxidants will allow the body to eliminate and or decrease the damage caused by free radicals (oxidative stress). Anti-oxidants are substances that are generally ingested and provide electrons to bind with dangerous free radicals and neutralize them in order for the body to dispose of them.

Different parts of the body are protected by different antioxidants. Structures containing lipids (fats) are mainly protected by the fat soluble vitamins A and E, whereas the water-soluble vitamin C helps us against free radicals in the blood, body fluids and within cells. If there was a method by which countless negatively charged ions could be delivered into your body (most of us aren't getting it from our cooked processed food diets anymore) would it not be totally beneficial. In the recent past, everyone was scrambling to find powerful anti-oxidants. The cause of aging, along with most of humanity's diseases, has been determined to be due, in large part, to actions of free radicals on our body.

We need to know which events speed up the pace of telomere shortening late in life although it can be associated with the cell's ability to withstand oxidative damage [65]. Meanwhile, the observed reduction in telomerase activity likely contributes to the acceleration in telomere erosion [67]. Therefore by the more antioxidants present in the body the less damage that occurs to the chromosome [68-71]. Telomere length is also directly related to life span and incidence of disease [72].

### **Which animal models have more similarities in telomere and telomerase biology with humans?**

In contrast to human, rodent telomeres are generally much longer and express telomerase in many tissues. Telomere shortening is broadly studied in mice, especially in telomerase knockout mice [73, 74]. However, it is only after 4-6 generations that telomere shortening becomes a critical issue in these mice, indicating mechanisms of carcinogenesis and ageing [75]. The rapid death following reproduction observed in rodent especially mouse species is much different and so these model organisms are not a good representative of human aging mechanisms, however, scientists noticed that rat telomeres do not have to be modulated to detect shortening, so the rat model might be more feasible than mice in studying the effect of oxidative stress and ageing. Telomere length assessed in Wistar rats in the kidney, liver, lung and brain may determine life span (longevity). It was found that male rats have shortened life span compared to females [76, 77]. Telomere length has been investigated in dogs, cats, bird species, horses, and cattle as animal models for applicability of the research to human telomere and telomerase activity. These animals have been observed that does share more similarities in telomere and telomerase biology with humans [78-90].

## CONCLUSION

People should be aware of the biological hazard and adverse health effects of EMFs as life stress. These studies have shown that electromagnetic fields as part of human daily lives can speed up the shortening of our protective telomeres and the ageing process because of chronic oxidative stress caused by free radicals, and people who rely on supplements and have a diet rich in major natural antioxidants or a good mixture of fruit and vegetables with high in antioxidants to help reduce the effects of these waves will live longer and healthier than those who don't.

However, although there is a long way to be able to assess the effects of environmental factors in life span, there is a need for more research on genetic determinants of telomere stability and other intrinsic and extrinsic factors leading to cell senescence and also the role of telomere shortening on inflammatory diseases progression, cancer and the various factors, such as heredity and other ageing.

## Acknowledgements

This work was supported by department of physiology, faculty of veterinary medicine, Atatürk University, Turkey.

## Competing interests

The authors declare that they have no competing interests.

## REFERENCES

1. Lerchl A, Krüger H, Niehaus M, Streckert JR, Bitz AK, Hansen V. 2008. Effects of mobile phone electromagnetic fields at non thermal SAR values on melatonin and body weight of Djungarian hamsters (*Phodopus sungorus*). *J Pineal Res*, 44: 267-272.
2. Hirata A., Watanabe H., Shiozawa T. 2002. SAR and temperature increase in the human eye induced by obliquely incident plane waves. *IEEE Trans Electromagn C*, 4: 592-594.
3. Koyu A, Cesur G, Özgüner F, Akdogan M, Mollaoğlu H, Özen Ş. 2005. Effects of 900 MHz electromagnetic field on TSH and thyroid hormones in rats. *Toxicol Lett*, 157: 257-262.
4. Özen Ş. 2003. Mikrodalga frekanslı EM radyasyona maruz kalan biyolojik dokularda oluşan ısı etkinin teorik ve deneysel incelenmesi. PhD Thesis; Department of Biology, University of Sakarya, Turkey.
5. Koyu A., Cesur G., Özgüner F., Elmas O. 2005. Cep telefonlarından yayılan 900 MHz elektromanyetik alanine serum kortizol ve testosteron hormonu üzerine etkisi. *S.D.U. Tip Fak Derg* (Medical Journal of Suleyman Demirel University, Turkey), 12: 52-56.
6. Lai H. 1992. Research on the neurological effects of nonionizing radiation at the University of Washington. *Bioelectromagnetics*, 13: 513-526.
7. Lee JS, Ahn SS, Jung KC, Kirn YW, Lee SK. 2004. Effects of 60 Hz electromagnetic field exposure on testicular germ cell apoptosis in mice. *Asian J Androl*, 6: 29-34.
8. Squires EJ. 2003. Applied Animal Endocrinology, London, *CABI Publishing*, 209: 96-97.
9. Koyu A, Gökalp O, Özgüner F, Cesur G, Mollaoğlu H, Özer MK, Çalışkan S. 2005. The effects of subchronic 1800 electromagnetic field exposure on the levels of TSH, T3, T4, cortisol and testosterone hormones. *Genel Tip Dergisi*, 15: 101-105.
10. Chemysheva ON. 1990. Status of the lipid phase of plasma membranes of the heart after repeated exposure to alternate magnetic of 50 Hz frequency. *Kosm Biol Aviakosm Med*, 24: 30-31.
11. Gorczynska E., Wegrzynowicz R. 1991. Glucose homeostasis in rats exposed to magnetic fields. *Invest Radiol*, 26: 1095-1100.
12. Radon K, Parera D, Rose DM, Jung D, Vollrath L. 2001. No effects of pulsed radio frequency electromagnetic fields on melatonin, cortisol, and selected markers of the immune system in man. *Bioelectromagnetics*, 4: 280-287.
13. Vangelova K, Israel M, Velkovaand D, Ivanova M. 2007. Changes in excretion rates of stress hormones in medical staff exposed to electromagnetic radiation. *Environmentalist*, 27: 551-555.
14. Lotfi AR and Shahryar HA, 2009. Effects of 900 MHz electromagnetic fields emitted by cellular phone on total cholesterol and triglyceride levels of plasma in syrian hamsters (*Mesocricetus auratus*). *J. Applied Biol. Sci.*, 3: 85-88.
15. Shahryar AH, Lotfi AR, Bahobj M and Karami AR, 2008. Effect of electromagnetic field of cellular phone on cortisol and testosterone hormones rate in Syrian hamsters. *Int. J. Zool. Res.*, 4: 230-233.
16. Bellossi A, Pouvreau-Quillien V, Rocher C and Ruelloux M, 1996. Effect of pulsed magnetic fields on cholesterol and frequency de levels in rats study of field intensity and length of exposure. *Z. Naturforsch [C]*, 51: 603-606.
17. Kula B., Sobczak A, Grabowska-bochenek R, Piskoska D. 1999. Effect of Electromagnetic field on serum biochemical parameters in steelworkers. *J Occup Health*. 41: 177-180.
18. Paredi P, Kharitonov SA, Hanazawa T, Barnes PJ. 2001. Local vasodilator response in mobile phones. *Laryngoscope*. 111: 159-162.
19. Sadeghi H, Zare S, Hayatgeibi H, Alivandi S and Ebadi AG, 2006. Biological effect of power frequency magnetic fields on serum biochemical parameters in guinea pigs. *Pakistan J. Biol. Sci.*, 6: 1083-1087.
20. Öcal I, Kalkan T, Günay I. 2008. Effects of alternating magnetic Field on the metabolism of the healthy and diabetic organisms. *Brazilian Arch. Biol. Technol.*, 51: 523-530.
21. Agarwal A, Prabakaran S, Allamaneni SS. 2006. Relationship between oxidative stress, varicocele and infertility: A meta-analysis. *Reprod Biomed Online*; 12: 630-3.

22. Aghdam Shahryar H and Lotfi AR. 2010. Effects of exposure to 900MHz electromagnetic fields emitted by cellular phone on secondary sex-ratio of male syrian hamsters (*Mesocricetus Auratus*). *Adv. Environ. Biol.*, 4: 305-307.
23. Shams Lahijani M. and Sajadi K. 2004. Development of preincubated chicken eggs following exposure to 50 Hz electromagnetic fields with 1.33-7.32 mT flux densities. *Indian J. Exp. Biol.*, 42: 866-870.
24. Ingole IV and Ghosh SK. 2006. Exposure to radio frequency radiation emitted by cell phone and mortality in chick embryos (*Gallus domesticus*). *Biomed Res*, 17: 205-210.
25. Batellier, F., Couty I, Picard D and Brillard JP. 2008. Effects of exposing chicken eggs to a cell phone in "call" position over the entire incubation period. *Theriogenology*, 69: 737-745.
26. Cuppen JJM, Wiegertjes GF, Lobe HWJ, Savelkoul HFJ, Elmusharaf MA, Beynen AC, Grooten HNA and Smink W. 2007. Immune stimulation in fish and chicken through weak low frequency electromagnetic fields. *Environmentalist*, 27: 577-583.
27. Yalcin S and Siegel PB. 2003. Exposure to cold and heat during incubation on developmental stability of broiler embryos. *Poult. Sci.*, 82: 1388-1392.
28. Lundy H. 1969. A review of the effects of temperature, humidity and gaseous exchange environment in the incubator on the hatchability of the hen's eggs. In: Carter, T.C. and B.M. Freeman (eds.), *The Fertility and Hatchability of the Hen's Egg*, pp: 143-176. Oliver and Boyd, Edinburgh, UK.
29. Shafey TM. 2006. Effect of lighted incubation on embryonic growth and hatchability performance of two strains of layer breeder eggs. *British Poult Sci*, 45: 223-229.
30. Shafey TM, Shalaby MI and Bayoumi MS 2007. Effects of Electric Field during Incubation of Eggs on the Hatchability and Post-Hatch Performance of Meat Chickens. *Int. J. Poult. Sci.*, 6: 1-7.
31. Elmusharaf MA, Cuppen JJ, Grooten HNA and Beynen AC, 2007. Antagonistic Effect of Electromagnetic Field Exposure on Coccidiosis Infection in Broiler Chickens. *Poult Sci*, 86: 2139-2143.
32. Pisiriciler R, Körpınar M, Toprak A, Kalkan N and Tunaya M. 2000. Düşük frekanslı elektromanyetik alanın tavuk embriyo hücrelerine etkisi. *Istanbul University Vet. Fak. Derg.*, 4: 1-7.
33. Boorman, GA, Gauger JR, Johnson TR, Tomlinson MJ, Findly JC, Travlos GS and McCormick DL. 1997. Eight-Week Toxicity Study of 60 Hz Magnetic Fields in F344rats and B6C3F1 Mice. *Fundam. Appl. Toxicol.*, 35: 55-63.
34. Erpek S, Bilgin MD and Kacar F. 2007. Elektromanyetik alanın (50 Hz, 6 mT) sıçan karaciğer ve böbreğine etkileri. *Adnan Menderes Üniversitesi Tıp. Fak. Derg*, 8: 5-11.
35. Suksaweang S, Lin C, Jiang T, Hughes MW, Widelitz RB and Chuong C. 2003. Morphogenesis of chicken liver: identification of localized growth zones and the role of  $\beta$ -catenin/Wnt in size regulation. *Develop Biol.*, 266: 109-122.
36. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. 1998. Extension of life-span by introduction of telomerase into normal human cells. *Science*, 279: 349-352.
37. Johnson FC. 1979. The antioxidant vitamins CRC. *Crit Rev Food Sci Nutr*, 11: 217-309.
38. Yoganathan T, Eskild W, Hansson V. 1989. Investigation of detoxification capacity of rat testicular germ cells and Sertoli cells. *Free Radic Biol Med*, 7: 355-9.
39. Paolicchi A, Pezzini A, Saviozzi M, et al. 1996. Localization of a GSH-dependent dehydroascorbate reductase in rat tissues and subcellular fractions. *Arch Biochem Biophys*, 333: 489-95.
40. Sonmez M, Turk G, Yuce A. 2005. The effect of ascorbic acid supplementation on sperm quality, lipid peroxidation and testosterone levels of male Wistar rats. *Theriogenology*, 63: 2063-72.
41. Senthil kumar J, Banudevi S, Sharmila M, et al. 2004. Effects of Vitamin C and E on PCB (Aroclor 1254) induced oxidative stress, androgen binding protein and lactate in rat Sertoli cells. *Reprod Toxicol*, 19: 201-8.
42. Maneesh M, Jayalakshmi H, Dutta S, et al. 2005. Experimental therapeutic intervention with ascorbic acid in ethanol induced testicular injuries in rats. *Indian J Exp Biol*, 43: 172-6.
43. Rao M, Narayana K, Benjamin S, et al. 2005. L-ascorbic acid ameliorates postnatal endosulfan induced testicular damage in rats. *Indian J Physiol Pharmacol*, 49: 331-6.
44. Chang SI, Jin B, Youn P, et al. 2007. Arsenic-induced toxicity and the protective role of ascorbic acid in mouse testis. *Toxicol Appl Pharmacol*, 218: 196-203.
45. Sen Gupta R, Sen Gupta E, et al. 2004. Vitamin C and vitamin E protect the rat testes from cadmium-induced reactive oxygen species. *Mol Cells*, 17: 132-9.
46. Verma RJ, Nair A. 2001. Ameliorative effect of vitamin E on aflatoxin-induced lipid peroxidation in the testis of mice. *Asian J Androl*, 3: 217-221.
47. Aruldas MM, Subramanian S, Sekar P, et al. 2005. Chronic chromium exposure-induced changes in testicular histoarchitecture are associated with oxidative stress: Study in a non-human primate (*Macaca radiata* Geoffroy). *Hum Reprod*, 20: 2801-13.
48. Marchlewicz M, Wiszniewska B, Gonet B, et al. 2007. Increased lipid peroxidation and ascorbic acid utilization in testis and epididymis of rats chronically exposed to lead. *Biomaterials*, 20: 13-9.
49. Lucasoli F, Fraga CG. 1999. Oxidative stress in testes of rats subjected to chronic iron intoxication and alpha-tocopherol supplementation. *Toxicology*, 132: 179-86.
50. Gavazza MB, Catala A. 2006. The effect of alpha-tocopherol on lipid peroxidation of microsomes and mitochondria from rat testis. *Prostaglandins Leukot Essent Fatty Acids*, 74: 247-54.
51. Ghosh D, Das UB, Misro M. 2002. Protective role of alpha-tocopherol-succinate (provitamin-E) in cyclophosphamide induced testicular gametogenic and steroidogenic disorders: A correlative approach to oxidative stress. *Free Radic Res*, 36: 1209-18.
52. Latchoumycandane C, Mathur PP. 2002. Effects of vitamin E on reactive oxygen species-mediated 2,3,7,8-tetrachlorodi-benzo-p-dioxin toxicity in rat testis. *J Appl Toxicol*, 22: 345-51.
53. Manna I, Jana K, Samanta PK. 2004. Intensive swimming exercise-induced oxidative stress and reproductive dysfunction in male wistar rats: Protective role of alpha-tocopherol succinate. *Can J Appl Physiol*, 29: 172-85.

54. Jedlinska-Krakowska M, Bomba G, et al. 2006. Impact of oxidative stress and supplementation with vitamins E and C on testes morphology in rats. *J Reprod Dev*, 52: 203-9.
55. Zhou DX, Qiu SD, Zhang J, et al. 2006. The protective effect of vitamin E against oxidative damage caused by formaldehyde in the testes of adult rats. *Asian J Androl*, 8: 584-8.
56. Houben MJM, Moonen HJJ, van Schooten FJ, Hageman GJ. 2008. Telomere length assessment: biomarker of chronic oxidative stress? Review. *Free Radic Biol Med*, 44: 235-246.
57. Furumoto K, Inoue E, Nagao N, Hiyama E, Miwa N. Age-dependent telomere shortening is slowed down by enrichment of intracellular vitamin C via suppression of oxidative stress. *Life Sci*, 3: 935-948, 1998.
58. Kashino G, Kodama S, Nakayama Y, Suzuki K, Fukase K, Goto M, Watanabe M. 2003. Relief of oxidative stress by ascorbic acid delays cellular senescence of normal human and Werner syndrome fibroblast cells. *Free Radic Biol Med*, 35: 438-443.
59. Yudoh K, Nguyen T, Nakamura H, Hongo-Masuko K, Kato T, Nishioka K. 2005. Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: oxidative stress induces chondrocyte telomere instability and down regulation of chondrocyte function. *Arthritis Res Ther*, 7: R380-R391.
60. Strehlow K, Rotter S, Wassmann S, Adam O, Grohe C, Laufs K, Bohm M, Nickenig G. 2003. Modulation of antioxidant enzyme expression and function by estrogens. *Circ Res*, 93: 170-177.
61. Tarry-Adkins JL, Ozanne SE, Norden A, Cherif H, Hales CN. 2006. Lower antioxidant capacity and elevated P53 and p21 may be a link between gender in renal telomere shortening, albuminuria, and longevity. *Am J Physiol Renal Physiol* 290:F509-F516.
62. Borrás C, Steve JM, Vina JR, Sastre J, Vina J, Pallardo FV. 2004. Glutathione regulates telomere activity in 3T3 fibroblasts. *J Biol Chem* 279: 34332-34335.
63. La Torre F, Silipigni A M, Orlando A, La Torre I, Aragona M. 1997. Role of free radicals, telomeres, and telomerases in aging and cancerogenesis. *Minerva Med*, May 88(5): 205-214.
64. Li S, Nosrati M, Kashani-Sabet M. 2007. Knockdown of Telomerase RNA Using Hammerhead Ribozymes and RNA Interference. *Methods in Molecular Biology*, 405:p.113-131.
65. Souza P D, Kirkwood T B. 2001. A stochastic model of cell replicative senescence based on telomere shortening, oxidative stress, and somatic mutations in nuclear and mitochondrial DNA. *J Theoretical Biology*, 213: 573-576.
66. Flores I, Canela A, Vera, E, Tejera, A, Cotsarelis G, Blasco MA. 2008. The longest telomeres: a general signature of adult stem cell compartments. *Genes Dev*. 22: 654-667.
67. Serra V, Grune T, Sitte N, Saretzki G, von Zglinicki T. 2000. Telomere length as a marker of oxidative stress in primary human fibroblast cultures. *Annals of the New York Academy of Sciences*, 908: 327-330.
68. Kashino G, Kodama S, Nakayama Y, Suzuki K, Fukase K, Goto M, Watanabe M. 2003. Relief of oxidative stress by ascorbic acid delays cellular senescence of normal human and Werner syndrome fibroblast cells. *Free Radic Biol Med*, 35: 438-443.
69. Furumoto K, Inoue E, Nagao N, Hiyama E, Miwa N. 1998. Age-dependent telomere shortening is slowed down by enrichment of intracellular vitamin C via suppression of oxidative stress. *Life Sci*, 3: 935-948.
70. Tarry-Adkins JL, Ozanne SE, Norden A, Cherif H, Hales CN. 2006. Lower antioxidant capacity and elevated P53 and p21 may be a link between gender in renal telomere shortening, albuminuria, and longevity. *Am J Physiol Renal Physiol*, 290:F509-F516.
71. Farzaneh-Fqar R, Lin J, Epel E S, Harris W S, Blackburn E H, Whooley M A. 2010. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. *JAMA*. 303(3): 250-257
72. Benetos A, Okuda K, Lajemi M, Kimura M, Thomas F, et al. 2001. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. *Hypertension*, 37: 381-385.
73. Blasco MA. 2005. Mice with bad ends: mouse models for the study of telomeres and telomerase in cancer and aging. *EMBO J* 24: 1095-1103.
74. Xin Z, Broccoli D. 2004. Manipulating mouse telomeres: models of tumorigenesis and aging. *Cytogenet Genome Res*, 105: 471-478.
75. Cherif H, Tarry JL, Ozanne SE, Hales CN. 2003. Ageing and telomeres: a study into organ- and gender-specific telomere shortening. *Nucleic Acid Res*, 31: 1576-1583.
76. Hastings R, Li NC, Lacy PS, Patel H, Herbert KE, Stanley AG, Williams B. 2004. Rapid telomere attrition in cardiac tissue of the ageing Wistar rat. *Exp Gerontol*, 39: 855-857.
77. Jennings BJ, Ozanne SE, Dorling MW, Hales CN. 1999. Early growth determines the longevity in male rats and may be related to telomere shortening in the kidney. *FEBS Lett*, 448: 4-8.
78. Nasir L, Devlin P, McKeivitt T, Rutteman G, Argyle DJ. 2001. Telomere lengths and telomerase activity in dog tissues: a potential model system to study human telomere and telomerase biology. *Neoplasia*, 3: 351-359.
79. Haussmann MF, Winkler DW, O'Reilly KM, Huntington CE, Nisbet LC, Vleck CM. 2003. Telomeres shorten more slowly in long-lived birds and mammals than in short-lived ones. *Proc Biol Sci*, 270: 1387-1392.
80. Nordfjall K, Larefalk A, Lindgren P, Holmberg D, Roos G. 2005. Telomere length and heredity: indications of paternal inheritance. *Proc Natl Acad Sci USA*, 102: 16374-16378.
81. Raynaud CM, Sabatier L, Phillipot O, Olausson KA, Soria JC. 2008. Telomere length, telomere proteins and genomic stability during the multistep carcinogenic process. Review. *Crit Rev Oncol Hematol*, 66: 99-117.
82. Houben MJM, Moonen HJJ, van Schooten FJ, Hageman GJ. 2008. Telomere length assessment: Biomarker of chronic oxidative stress? Review. *Free Radic Biol Med*, 44: 235-246.
83. Aviv A. 2008. The epidemiology of human telomeres: faults and promises. Review. *J Gerontol A Biol Sci Med Sci*, 63: 979-983.
84. von Figura G, Hartmann D, Song Z, Rudolph KL. 2009. Role of telomere dysfunction in aging and its detection by biomarkers. Review. *J Mol Med*, 87: 1165-1171.
85. Lansdorp PM. 2009. Telomeres and disease. Review. *EMBO J*, 28: 2532-2540.
86. Cherif H, Tarry JL, Ozanne SE, Hales CN. 2003. Ageing and telomeres: a study into organ- and gender-specific telomere shortening. *Nucleic Acids Res*, 31(5): 1576-1583.
87. Flores I, Blasco MA. 2010. The role of telomeres and telomerase in stem cell aging. *FEBS Lett.*, 584(17): 3826-30. doi: 10.1016/j.febslet.2010.07.042.

88. Vera E, Bernardes de Jesus B, Foronda M, Flores JM, Blasco MA. 2012. The rate of increase of short telomeres predicts longevity in mammals. *Cell Rep*, 2(4): 732-7. doi: 10.1016/j.celrep.2012.08.023.
89. Wanat JJ, Johnson FB. 2012. Telomere stability and carcinogenesis: an off-again, on-again relationship. *J Clin Invest*, 122(6): 1962–1965. <http://doi.org/10.1172/JCI63979>
90. Asghari A, Khaki AA, Rajabzadeh A, Khaki A. 2016. A review on Electromagnetic fields (EMFs) and the reproductive system. *Electronic Physician*, 8(7): 2655–2662. <http://doi.org/10.19082/2655>

# Instructions for Authors

Manuscript as Original Research Paper, Review and Case Reports are invited for rapid peer-review publishing in the *Journal of Life Science and Biomedicine*. Considered subject areas include: Biocontrol, Biochemistry, Biotechnology, Bioengineering, Neurobiology... [view full aims and scope](#)

[JLSB EndNote Style](#)

[Manuscript Template \(.doc\)](#)

[Sample Articles](#)

[Declaration form](#)

[Policies and Publication Ethics](#)

## Submission

The manuscript and other correspondence should preferentially be [submit online](#). Please embed all figures and tables in the manuscript to become one single file for submission. Once submission is complete, the system will generate a manuscript ID and will send an email regarding your submission. Meanwhile, the authors can submit or track articles via [editors@jlsb.science-line.com](mailto:editors@jlsb.science-line.com) ; [jlsb.editors@gmail.com](mailto:jlsb.editors@gmail.com). All manuscripts must be checked (by English native speaker) and submitted in English for evaluation (in totally confidential and impartial way).

## Supplementary information

The online submission form allows supplementary information to be submitted together with the main manuscript file and covering letter. If you have more than one supplementary files, you can submit the extra ones by email after the initial [submission](#). Author guidelines are specific for each journal. Our Word template can assist you by modifying your page layout, text formatting, headings, title page, image placement, and citations/references such that they agree with the guidelines of journal. If you believe your article is fully edited per journal style, please use our [MS Word template](#) before submission. **Supplementary materials** may include figures, tables, methods, videos, and other materials. They are available online linked to the original published article. Supplementary tables and figures should be labeled with a "S", e.g. "Table S1" and "Figure S1". The maximum file size for supplementary materials is 10MB each. Please keep the files as small possible to avoid the frustrations experienced by readers with downloading large files.

## Submission to the Journal is on the understanding that

- 1.The article has not been previously published in any other form and is not under consideration for publication elsewhere;
- 2.All authors have approved the submission and have obtained permission for publish work.
- 3.Researchers have proper regard for conservation and animal welfare considerations. Attention is drawn to the '[Guidelines for the Treatment of Animals in Research and Teaching](#)'. Any possible adverse consequences of the work for populations or individual organisms must be weighed against the possible gains in knowledge and its practical applications. If the approval of an ethics committee is required, please provide the name of the committee and the approval number obtained.

## Ethics Committee Approval


Experimental research involving human or animals should have been approved by author's institutional review board or ethics committee. This information can be mentioned in the manuscript including the name of the board/committee that gave the approval. Investigations involving humans will have been performed in accordance with the principles of [Declaration of Helsinki](#). And the use of animals in experiments will have observed the *Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education* by the New York Academy of Sciences, Ad Hoc Animal Research Committee. If the manuscript contains photos or parts of photos of patients, informed consent from each patient should be obtained. Patient's identities and privacy should be carefully protected in the manuscript.

## Graphical Abstract

Authors should provide a graphical abstract (a beautifully designed feature figure) to represent the paper aiming to catch the attention and interest of readers. Graphical abstract will be published online in the table of content. The graphical abstract should be colored, and kept within an area of 12 cm (width) x 6 cm (height) or with similar format. Image should have a minimum resolution of 300 dpi and line art 1200dpi.

**Note:** Height of the image should be no more than the width.

Please avoid putting too much information into the graphical abstract as it occupies only a small space. Authors can provide the graphical abstract in the format of PDF, Word, PowerPoint, jpg, or png, after a manuscript is accepted for publication. For preparing a Professional Graphical Abstract, please click [here](#).



## Presentation of the article

### Main Format

First page of the manuscripts must be properly identified by the title and the name(s) of the author(s). It should be typed in Times New Roman (font sizes: 17pt in capitalization for the title, 10pt for the section headings in the body of the text and the main text, double spaced, in A4 format with 2cm margins (both doc./docx formats). All pages and lines of the main text should be numbered consecutively throughout the manuscript. Abbreviations in the article title are not allowed. Manuscripts should be arranged in the following order:

1. **TITLE** (brief, attractive and targeted)
2. **Name(s) and Affiliation(s) of author(s)** (including post code and corresponding Email)
3. **ABSTRACT**
4. **Key words** (separate by semicolons; or comma,)
5. **Abbreviations** (those used throughout the manuscript)
6. **INTRODUCTION** (clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution)
7. **MATERIAL AND METHOD** (should be complete enough to allow experiments to be reproduced)
8. **RESULTS**
9. **DISCUSSION**
10. **CONCLUSION**
11. **DECLARATIONS** (Acknowledgements, Consent to publish, Competing interests, Authors' contributions, and Availability of data etc.)
12. **REFERENCES**
13. **Tables**
14. **Figures**
15. **Graphs**

Results and Discussion can be presented jointly.

Discussion and Conclusion can be presented jointly.

### Article Sections Format

**Title** should be a brief phrase describing the contents of the paper. The first letter of each word in title should use upper case. The Title Page should include the author(s)'s full names and affiliations, the name of the corresponding author along with phone and e-mail information. Present address (es) of author(s) should appear as a footnote.

**Abstract** should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The abstract should be 150 to 300 words in length. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited.

Following the abstract, about 3 to 8 **key words** that will provide indexing references should be listed.

**Introduction** should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines.

**Material and Method** should be complete enough to allow experiments to be reproduced. However, only truly new procedures should be described in detail; previously published procedures should be cited, and important modifications of published procedures should be mentioned briefly. Capitalize trade names and include the manufacturer's name and address. Subheadings should be used. Methods in general use need not be described in detail. The **ethical approval** for using human and animals in the researches should be indicated in this section with a separated title.

**Results** should be presented with clarity and precision. The results should be written in the past tense when describing findings in the author(s)'s experiments. Previously published findings should be written in the present tense. Results should be explained, but largely without referring to the literature. In case of the effectiveness of a particular drug or other substances as inhibitor in biological or biochemical processes, the results should be provided as **IC<sub>50</sub> (half maximal inhibitory concentration)** or similar appropriate manner.

**Discussion** should interpret the findings in view of the results obtained in this and in past studies on this topic. State the conclusions in a few sentences at the end of the paper. The Results and Discussion sections can include subheadings, and when appropriate, both sections can be combined.

**Conclusion** should be brief and tight about the importance of the work or suggest the potential applications and extensions. This section should not be similar to the Abstract content.

**Declarations** including Acknowledgements, Author contribution, Competing interests, Consent to publish, and Availability of data etc.

**Tables** should be kept to a minimum and be designed to be as simple as possible. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. The details of the methods used in the experiments should preferably be described in the legend instead of in the text. The same data should not be presented in both table and graph forms or repeated in the text.

**Figure legends** should be typed in numerical order on a separate sheet. Graphics should be prepared using applications capable of generating high resolution GIF, TIFF, JPEG or PowerPoint before pasting in the Microsoft Word manuscript file. Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.

## Declarations

Please ensure that the sections: Ethics (and consent to participate, if any), Acknowledgements, Author contribution, Competing interests, Consent to publish, Availability of data and materials are included at the end of your manuscript in a Declarations section.

## Acknowledgements

We encourage authors to include an Acknowledgements section. Please acknowledge anyone who contributed towards the study by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship. Please also include their source(s) of funding. Please also acknowledge anyone who contributed materials essential for the study. Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements. Please list the source(s) of funding for the study, for each author, and for the manuscript preparation in the acknowledgements section. Authors must describe the role of the funding body, if any, in study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.

## Author contribution

For manuscripts with more than one author, JLSB require an Author Contributions section to be placed after the Acknowledgements section. An 'author' is generally considered to be someone who has made substantive intellectual contributions to a published study. To qualify as an author one should 1) have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) have been involved in drafting the manuscript or revising it critically for important intellectual content; and 3) have given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship. **We suggest the following format/example** (please use initials to refer to each author's contribution): AB carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. JY carried out the immunoassays. MT participated in the sequence alignment. ES participated in the design of the study and performed the statistical analysis. FG conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

For authors that equally participated in a study please write 'All/Both authors contributed equally to this work.' Contributors who do not meet the criteria for authorship should be listed in an acknowledgements section.

## Competing interests

Competing interests that might interfere with the objective presentation of the research findings contained in the manuscript should be declared in a paragraph heading "Competing interests" (after Acknowledgment or Author Contribution sections). Examples of competing interests are ownership of stock in a company, commercial grants, board membership, etc. If there is no competing interest, please use the statement "The authors declare that they have no competing interests.".

*Journal of Life Science and Biomedicine* adheres to the definition of authorship set up by [The International Committee of Medical Journal Editors \(ICMJE\)](#). According to the ICMJE authorship criteria should be based on 1) substantial contributions to conception and design of, or acquisition of data or analysis and interpretation of data, 2) drafting the article or revising it critically for important intellectual content and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. It is a requirement that all authors have been accredited as appropriate upon submission of the manuscript. Contributors who do not qualify as authors should be mentioned under Acknowledgements.

## Consent to publish

Please include a 'Consent for publication section in your manuscript. If your manuscript contains any individual person's data in any form (including individual details, images or videos), consent to publish must be obtained from that person, or in the case of children, their parent or legal guardian. All presentations of case reports must have consent to publish. You can use your institutional consent form or our consent form if you prefer. You should not send the form to us on submission, but we may request to see a copy at any stage (including after publication). If your manuscript does not contain any individual persons data, please state "Not applicable" in this section.

## Change in authorship

We do not allow any change in authorship after provisional acceptance. We cannot allow any addition, deletion or change in sequence of author name. We have this policy to prevent the fraud.

## Data deposition

Nucleic acid sequences, protein sequences, and atomic coordinates should be deposited in an appropriate database in time for the accession number to be included in the published article. In computational studies where the sequence information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published as an additional file with the article.

## REFERENCES

A JLSB reference style for [EndNote](#) may be found [here](#). However, we prefer [Vancouver](#) referencing style that is often used in medicine and the natural sciences. Uniform requirements for manuscripts submitted to Biomedical Journals, published by International Committee of Medical Journal Editors, includes a list with examples of references [https://www.nlm.nih.gov/bsd/uniform\\_requirements.html](https://www.nlm.nih.gov/bsd/uniform_requirements.html) in the *Vancouver* style.

References should be numbered consecutively and cited in the text by number in square brackets [1, 2] instead of parentheses (and not by author and date). References should not be formatted as footnotes. Avoid putting personal communications and unpublished observations as references. All the cited papers in the text must be listed in References. All the papers in References must be cited in the text. Where available, URLs for the references should be provided.

## Examples (at the text, blue highlighted)

Smit [1] ...; Smit and Janak [2]...; Nurai et al. [3] reported that ; ... [1], --- [2, 3], --- [3-7]. The references at the end of this document are in the preferred referencing style. Give all authors' names; do not use "et al." unless there are six authors or more. Use a space after authors' initials. Papers that have not been published should be cited as "unpublished". Papers that have been accepted for publication, but not yet specified for an issue should be cited as "to be published". Papers that have been submitted for publication should be cited as "submitted for publication". Capitalize only the first word in a paper title, except for proper nouns and element symbols. For papers published in translation journals, please give the English citation first, followed by the original foreign-language citation.

## Acceptable Examples (at References section)

### For Journals:

1. Hasan V, Sri Widodo M and Semedi B. 2015. Oocyte diameter distribution and fecundity of Javaen Barb (*Systomus Orphoides*) at the start of rainy season in Lenteng River, East Java, Indonesia insurance. J. Life Sci Biomed, 5(2): 39-42. DOI, Link
2. Karen KS, Otto CM. 2007. Pregnancy in women with valvular heart disease. Heart. 2007 May; 93(5): 552-558. DOI, Link
3. Doll MA, Salazar-González RA, Bodduluri S, Hein DW. Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes. Acta Pharm Sin B, 2017; 7(4):517-522. DOI, Link

### For In press manuscripts (maximum 2):

Hasan V, Sri Widodo M and Semedi B. 2015. Oocyte Diameter Distribution and Fecundity of Javaen Barb (*Systomus Orphoides*) at the Start of Rainy Season in Lenteng River, East Java, Indonesia insurance. In press.

### For symposia reports and abstracts:

Cruz EM, Almatar S, Aludul EK and Al-Yaqout A. 2000. Preliminary Studies on the Performance and Feeding Behaviour of Silver Pomfret (*Pampus argentens euphrasen*) Fingerlings fed with Commercial Feed and Reared in Fibreglass Tanks. Asian Fisheries Society Manila, Philippine 13: 191-199. DOI, Link

### For Conference:

Skinner J, Fleener B and Rinchiuso M. 2003. Examining the Relationship between Supervisors and Subordinate Feeling of Empowerment with LMX as A Possible Moderator. 24th Annual Conference for Industrial Organizational Behavior. DOI, Link

### For Book:

Russell, Findlay E, 1983. Snake Venom Poisoning, 163, Great Neck, NY: Scholium International. ISBN 0-87936-015-1. DOI, Link

### For Web Site:

Bhatti SA and Firkins JT. 2008. [http://www.ohioline.osu.edu/sc1156\\_27.html](http://www.ohioline.osu.edu/sc1156_27.html). DOI, Link

## Nomenclature and Abbreviations

Nomenclature should follow that given in NCBI web page and Chemical Abstracts. Standard abbreviations are preferable. If a new abbreviation is used, it should be defined at its first usage. Abbreviations should be presented in one paragraph, in the format: "term: definition". Please separate the items by ";".

E.g. ANN: artificial neural network; CFS: closed form solution; ...

Abbreviations of units should conform with those shown below:

Decilitre	dl	Kilogram	kg
Milligram	mg	hours	h
Micrometer	mm	Minutes	min
Molar	mol/L	Mililitre	ml
Percent	%	.	

Other abbreviations and symbols should follow the recommendations on units, symbols and abbreviations: in "A guide for Biological and Medical Editors and Authors (the Royal Society of Medicine London 1977). Papers that have not been published should be cited as "unpublished". Papers that have been accepted for publication, but not yet specified for an issue should be cited as "to be published". Papers that have been submitted for publication should be cited as "submitted for publication".

## Formulae, numbers and symbols

1. Typewritten formulae are preferred. Subscripts and superscripts are important. Check disparities between zero (0) and the letter O, and between one (1) and the letter I.
2. Describe all symbols immediately after the equation in which they are first used.
3. For simple fractions, use the solidus (/), e.g. 10 /38.
4. Equations should be presented into parentheses on the right-hand side, in tandem.
5. Levels of statistical significance which can be used without further explanations are \*P < 0.05, \*\*P < 0.01, and \*\*\*P < 0.001.
6. In the English articles, a decimal point should be used instead of a decimal comma.
7. Use Symbol fonts for "±"; "≤" and "≥" (avoid underline).
8. In chemical formulae, valence of ions should be given, e.g. Ca<sup>2+</sup> and CO<sub>3</sub><sup>2-</sup>, not as Ca<sup>++</sup> or CO<sub>3</sub>.
9. Numbers up to 10 should be written in the text by words. Numbers above 1000 are recommended to be given as 10 powered x.
10. Greek letters should be explained in the margins with their names as follows: Αα - alpha, Ββ - beta, Γγ - gamma, Δδ - delta, Εε - epsilon, Ζζ - zeta, Ηη - eta, Θθ - theta, Ιι - iota, Κκ - kappa, Λλ - lambda, Μμ - mu, Νν - nu, Ξξ - xi, Οο - omicron, Ππ - pi, Ρρ - rho, Σσ - sigma, Ττ - tau, Υυ - ipsilon, Φφ - phi, Χχ - chi, Ψψ - psi, Ωω - omega. Please avoid using math equations in Word whenever possible, as they have to be replaced by images in xml full text.

## Review/Decisions/Processing/Policy

Firstly, all manuscripts will be checked by [Docol@c](#), a plagiarism finding tool. The received papers with plagiarism rate of more than 30% will be rejected. Manuscripts that are judged to be of insufficient quality or unlikely to be competitive enough for publication will be returned to the authors at the initial stage. The remaining manuscripts go through a single-blind review process by external reviewers selected by section editor of JLSB, who are research workers specializing in the relevant field of study. One unfavourable review means that the paper will not be published and possible decisions are: accept as is, minor revision, major revision, or reject. The corresponding authors should submit back their revisions within 14 days in the case of minor revision, or 30 days in the case of major revision. Manuscripts with significant results are typically published at the highest priority. The editor who received the final revisions from the corresponding authors shall not be hold responsible for any mistakes shown in the final publication.

The submissions will be processed free of charge for invited authors, authors of hot papers, and corresponding authors who are editorial board members of the *Journal of Life Science and Biomedicine*. This journal encourage the academic institutions in low-income countries to publish high quality scientific results, free of charges.

### Plagiarism

Manuscripts are screened for plagiarism by [Docol@c](#), before or during publication, and if found (more than 30% duplication limit) they will be rejected at any stage of processing. If we discovered accidental duplicates of published article(s) that are determined to violate our journal publishing ethics guidelines (such as multiple submission, bogus claims of authorship, plagiarism, fraudulent use of data or the like), the article will be "Withdrawn" from SCIENCELINE database. Withdrawn means that the article content (HTML and PDF) is removed and replaced with a HTML page and PDF simply stating that the article has been withdrawn according to the [Scienceline Policy](#) on Published Article Withdrawal.

### Date of issue

All accepted articles are published bimonthly around 25th of January, March, May, July, September and November, each year in full text on the internet.

### The OA policy

*Journal of Life Science and Biomedicine* is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the [BOAI definition of Open Access](#).

## Submission Preparation Checklist

- Authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to the following guidelines.
- The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
- The submission file is in Microsoft Word, RTF, or PDF document file format. Where available, URLs for the references have been provided.
- The text is single-spaced; uses a 12-point font; and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines.

## Paper Submission Flow




**Scienceline Publication** Ltd is a limited liability non-profit non-stock corporation incorporated in Turkey, and also is registered in Iran. Scienceline journals that concurrently belong to many societies, universities and research institutes, publishes internationally peer-reviewed open access articles and believe in sharing of new scientific knowledge and vital research in the fields of life and natural sciences, animal sciences, engineering, art, linguistic, management, social and economic sciences all over the world. Scienceline journals include:

## Online Journal of Animal and Feed Research



ISSN 2228-7701; Bi-monthly  
[View Journal](#) | [Editorial Board](#)  
 Email: [editors@ojafri.ir](mailto:editors@ojafri.ir)  
[Submit Online >>](#)

## Journal of Civil Engineering and Urbanism




ISSN 2252-0430; Bi-monthly  
[View Journal](#) | [Editorial Board](#)  
 Email: [ojceu@ojceu.ir](mailto:ojceu@ojceu.ir)  
[Submit Online >>](#)

## Journal of Life Sciences and Biomedicine




ISSN: 2251-9939; Bi-monthly  
[View Journal](#) | [Editorial Board](#)  
 Email: [editors@jlsb.science-line.com](mailto:editors@jlsb.science-line.com)  
[Submit Online >>](#)

## Asian Journal of Medical and Pharmaceutical Researches



ISSN: 2322-4789; Quarterly  
[View Journal](#) | [Editorial Board](#)  
 Email: [editor@ajmpr.science-line.com](mailto:editor@ajmpr.science-line.com)  
[Submit Online >>](#)

## Journal of World's Poultry Research




ISSN: 2322-455X; Quarterly  
[View Journal](#) | [Editorial Board](#)  
 Email: [editor@jwpr.science-line.com](mailto:editor@jwpr.science-line.com)  
[Submit Online >>](#)

## World's Veterinary Journal




ISSN: 2322-4568; Quarterly  
[View Journal](#) | [Editorial Board](#)  
 Email: [editor@wjv.science-line.com](mailto:editor@wjv.science-line.com)  
[Submit Online >>](#)

## Journal of Educational and Management Studies




ISSN: 2322-4770; Quarterly  
[View Journal](#) | [Editorial Board](#)  
 Email: [info@jems.science-line.com](mailto:info@jems.science-line.com)  
[Submit Online >>](#)

## Journal of World's Electrical Engineering and Technology



ISSN: 2322-5114; Irregular  
[View Journal](#) | [Editorial Board](#)  
 Email: [editor@jweet.science-line.com](mailto:editor@jweet.science-line.com)  
[Submit Online >>](#)

## Journal of Art and Architecture Studies



ISSN: 2383-1553; Irregular  
[View Journal](#) | [Editorial Board](#)  
 Email: [jaas@science-line.com](mailto:jaas@science-line.com)  
[Submit Online >>](#)

## Asian Journal of Social and Economic Sciences



ISSN: 2383-0948; Quarterly  
[View Journal](#) | [Editorial Board](#)  
 Email: [ajses@science-line.com](mailto:ajses@science-line.com)  
[Submit Online >>](#)

## Journal of Applied Business and Finance Researches



ISSN: 2382-9907; Quarterly  
[View Journal](#) | [Editorial Board](#)  
 Email: [jabfr@science-line.com](mailto:jabfr@science-line.com)  
[Submit Online >>](#)

## Scientific Journal of Mechanical and Industrial Engineering



ISSN: 2383-0980; Quarterly  
[View Journal](#) | [Editorial Board](#)  
 Email: [sjmie@science-line.com](mailto:sjmie@science-line.com)  
[Submit Online >>](#)